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The Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is an important virulence factor on
the surface of infected erythrocytes. Naturally acquired antibodies to PfEMP1 expressed by parasites causing
severe malaria are suggested to be protective and of major interest for the development of a vaccine against
severe disease. In this study, the PfEMP1 expressed by a parasite clone displaying a multiadhesive phenotype
associated with severe malaria was well recognized by sera of malaria semi-immune children. The efficiency of
the Duffy binding-like 1 (DBL1) domain of this PfEMP1 was therefore, alone or in combination with two
additional DBL1 domains, evaluated as a potential vaccine candidate using both a rodent model and a
primate model. Antibodies against the DBL1 domain were generated by immunization with recombinant
DBL1-Semliki Forest virus particles and recombinant protein and analyzed in vitro. The immunized animals
were challenged in vivo with various parasite strains or clones. Immunization with the PfEMP1-DBL1
domain abolished the PfEMP1-dependent sequestration of the homologous strain in immunized rats and
substantially inhibited parasite adhesion in immunized monkeys. Protection against sequestration of heter-
ologous parasite strains was also confirmed by direct or indirect challenge in the rat model. These results
strongly support the use of the DBL1 domain in the development of a vaccine targeting severe malaria.
The human malaria parasite Plasmodium falciparum is re-
sponsible for the death of 1.5 to 2 million individuals per year,
affecting mainly children under the age of 5 years (36). An
effective vaccine is urgently needed and would offer one of
the most promising long-term solutions in the combat
against malaria.
Cerebral malaria accounts for more than one-third of the
severe cases in African countries (21, 22). The primary cause of
cerebral malaria is the sequestration of infected erythrocytes
(iRBC) in the microvasculature of the brain (22) leading to
severe endothelial damage as frequently observed in postmor-
tem examination of patients (35, 37). Molecules or antibodies
able to block the interaction between parasite ligands and
human receptors that would provide therapeutic or preventive
treatment are still not available.
Parasites infecting children express different variants of vari-
able surface antigens leading to either mild or severe disease in
the host. Antigens associated with severe disease are fre-
quently recognized by sera from semi-immune individuals with
various exposures to the parasite indicating a strong associa-
tion between immune recognition of this virulent subtype of
antigens and immunity to clinical disease (4, 6, 8, 23, 24, 39).
Antibodies recognizing these surface antigens lead to a selec-
tion against the parasites expressing them (6), suggesting im-
munity develops first against variants associated with virulence
and severe disease, while an incomplete repertoire of these
specific antibodies makes the individual susceptible to severe
disease (6, 8, 23, 24, 39). The fact that P. falciparum erythro-
cyte membrane protein 1 (PfEMP1) variants of the severe
subtype tend to be more immunogenic and to be better
recognized than those of the uncomplicated subtype pro-
poses that these PfEMP1 molecules are promising vaccine
candidates potentially able to generate protective immunity
against severe disease.
The family of PfEMP1 is so far the only group of surface
antigens linked to the parasites’ ability to cytoadhere and se-
quester (2, 14, 26). PfEMP1 is a clonally variant antigen re-
sponsible for the antigenic variation at the iRBC surface (12,
34), with an extracellular part composed of various domains.
The Duffy binding-like domain 1 (DBL1) has the highest
degree of sequence conservation among all PfEMP1 domains
(18) and is an attractive candidate for the development of an
anti-severe malaria vaccine. Extensive analysis of the role of
PfEMP1 during sequestration has revealed the importance of
this domain for binding to different host receptors on RBC and
endothelial cells (13, 31, 40) and its role in parasite sequestra-
tion in the microvasculature (14, 26, 40). These interactions
have been linked to severe disease (9, 19, 25, 30), and immune
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responses to this PfEMP1 domain can be important for pro-
tection against severe and complicated malaria.
We have recently demonstrated that immunization with re-
combinant Semliki-Forest virus (SFV) particles encoding the
DBL1 domain of a parasite with a phenotype associated with
severe malaria (FCR3S1.2) generates functional and biologi-
cally active antibodies. They recognize the PfEMP1 on the
iRBC surface, disrupt parasite autoagglutinates and rosettes,
and block iRBC adhesion in vivo (14, 26). Here we have stud-
ied the immunogenicity of our DBL1 vaccine in a novel
sequestration model employing the nonhuman primate Macaca
fascicularis. Moreover, we have analyzed the potential of a
combination of several DBL1 domains (var1 of FCR3S1.2,
var1 of PAvarO, and var5.2 of 3D7) for their ability to induce
a broader, protective repertoire of antibodies in a small animal
model. Immunization with the recombinant SFV particles en-
coding the DBL1 domain induced strong humoral immune
responses that are cross-reactive to heterologous parasites. We
additionally confirmed the specific antibodies to substantially
block iRBC adhesion in the vasculature of the immunized
monkeys. Our data underline the importance of including the
DBL1 domain in a vaccine against severe malaria based on its
ability to induce antibodies mimicking those in children pro-
tected by naturally acquired immunity.
MATERIALS AND METHODS
Parasite strains and isolates from Kenya. The P. falciparum laboratory clone
FCR3S1.2 (17) and strains FCR3CSA (27), R29, Dd2, FCR3, PAvarO, and A4
(29) were cultivated as described previously (20). The phenotype of FCR3S1.2,
PAvarO, and R29 iRBC was maintained by weekly enrichment over a Ficoll
gradient (20), while FCR3CSA iRBC were frequently panned on chondroitin
sulfate A (CSA) to maintain the parasite phenotype.
Children attending Kilifi District Hospital (Kilifi, Kenya) with a primary di-
agnosis of malaria, but not fulfilling the criteria for severe malaria according to
Taylor et al. (38), were recruited for the study. If consent was obtained from the
child’s legal guardian, a blood sample for parasite isolation was drawn. After
collection, culturing was done according to standard methods; parasites were
harvested for fluorescence-activated cell sorting (FACS) analysis 24 to 28 h
postinvasion (p.i.).
Recognition of parasite strains/isolates by sera from semi-immune Kenyan
children. Fifty-eight sera from malarious, semi-immune children (Kilifi, Kenya;
approved by the legal guardians of the children) and control pools of sera from
local adults and healthy Europeans were tested for recognition of seven fresh
local parasite isolates from children (p78, 80, 83, 95, 1759, 3840, and 4687) and
two laboratory strains (FCR3S1.2 and A4). Trophozoite stages were tested in
serum dilutions of 1:5 by FACS analysis (EPIC/XL flow cytometer; Coulter
Electronics) after labeling with a fluorescein isothiocyanate (FITC)-conjugated
goat anti-human immunoglobulin (Ig) antibody (dilution of 1:100; The Binding
Site Limited, England) and 10 g/ml ethidium bromide, counting 1,000 iRBC.
All experiments followed the guidelines of conduct of clinical research and
were performed after informed consent of the children’s parents or guardians.
Ethical clearance was granted by the Kenya National Ethical Review Committee.
Production of recombinant SFV particles and recombinant proteins in Esch-
erichia coli. Three mini-var genes were created (for oligonucleotides, see Table
S1 in the supplemental material) combining the open reading frames of three
DBL1 domains with the transmembrane (TM) domain of the FCR3S1.2 var1
PfEMP1 as described before (14): (i) DBL1 domain of FCR3S1.2 var1 PfEMP1
(11); (ii) DBL1 domain of PAvarO var1 PfEMP1 (32); and (iii) DBL1 domain
encoded by var5.2 of the 3D7 P. falciparum clone (chromosome 5; PfE1640) (41).
Recombinant SFV particles were produced as described previously (14).
The DBL1 domains were in addition expressed as glutathione S-transferase
(GST) fusion proteins (vector pGEX-4T-1; AmershamPharmacia, Sweden) or
His-tagged fusion proteins (vector pQE-TriSystem; QIAGEN) and purified as
described previously (13).
Immunization of animals. Fifty male Sprague-Dawley rats (3 months old)
were assigned to five different groups (Table 1). Animals received three immu-
nizations with recombinant SFV particles on days 0, 30, and 60 (1 108 particles/
rat) and one immunization with recombinant protein emulsified in Montanide
ISO 720 (Seppic, France) on day 90 (100 g protein/rat) subcutaneously. Sera
were collected 4 weeks after the last immunization. Animals were challenged
with parasites between days 125 and 135 (permission no. N176/03).
Ten female cynomolgus macaques (Macaca fascicularis, 4 to 5 years old) were
housed at the Primate Research Center of the Swedish Institute for Infectious
Disease Control (permission no. N222/04 to N308/04). They were randomly
assigned into two groups (Table 1) and immunized three times by subcutaneous
administration of recombinant SFV particles on days 0, 28, and 56 (5  108
particles/animal) and once with recombinant protein (50 g protein/animal)
emulsified in Montanide ISO 720 on day 84. Blood samples were collected on
days 56, 84, and 105; all monkeys were challenged with iRBC on day 111 or 113.
TABLE 1. Scheme of animal immunization
Exptl. setup of group Antigen used forvaccination
No. of
animals
No. of
vaccinations Dose per vaccination
rSFV
particles Protein rSFV particles (no.) Protein (g)
Rats
Group 1 (1 DBL1 construct) DBL1 var1 FCR3S1.2 8 3 1 1  108 100
Group 2 (3 DBL1 constructs, mixed) DBL1 var1 FCR3S1.2 10 3 1 1  108 33 per antigen
DBL1 var1 PAvarO
DBL1 var5.2 3D7
Group 3 (3 DBL1 constructs, sequentially) DBL1 var1 FCR3S1.2 6 3 1 0.33  108 per antigen 33 per antigen
DBL1 var1 PAvarO
DBL1 var5.2 3D7
Group 4 (1 DBL1 construct) DBL1 var1 PAvarO 8 3 1 1  108 100
Group 5 (control) GST 12 3 1 1  108 100
Monkeys
Group A (1 DBL1 construct) DBL1 var1 FCR3S1.2 5 3 1 5  108 50
Group B (control) GST 5 3 1 5  108 50
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Challenge of immunized rats and monkeys with iRBC. Immunized rats were
challenged by intravenous infusion with various 99mtechnetium-labeled iRBC of
parasite strains according to an established protocol (14, 26). The amount of
sequestered iRBC was determined by relating the count rates of the separate
lungs to the whole-body count rates comparing DBL1- and GST-immunized
animals.
For indirect challenge, iRBC (1  107cells/rat) were, after labeling, incubated
with immune rat sera at dilutions of 1:2.5 to 1:40 at 37°C for 45 min prior to
injection into naı¨ve animals. The numbers of iRBC sequestered in these animals
were compared to controls, where incubation with sera from the control group
was performed.
Immunized monkeys were challenged according to a recently established
method (39a). Briefly, 99mTc-labeled human RBC or iRBC were injected
through a catheter into the vena saphena magna (1  108 cells/monkey). Images
were acquired for 15 min in a three-headed gamma camera starting 20 min after
injection of iRBC; anatomical three-dimensional pictures were simultaneously
obtained by X ray. The amount of material sequestered in the lungs was deter-
mined by overlaying the data collected with both systems. The background level
of uninfected human RBC binding was determined from one naı¨ve monkey,
while the level of specific sequestration in the animals was calculated from one
naı¨ve and four control-immunized monkeys. In order to reveal the inhibitory
effect on sequestration, the values were corrected for background-binding of
uninfected RBC and the amounts of iRBC in the lungs of DBL1- and GST-
immunized monkeys were compared.
Immunological analysis of anti-DBL1 antibody responses in immunized
monkeys. Enzyme-linked immunosorbent assays (ELISAs) were carried out as
described previously (13) using sera in double dilutions (1:1,000 to 1:64.000);
endpoint titers were determined comparing the reactivity of the sera against the
DBL1 domain and GST.
The presence of specific antibodies against the DBL1 domain was confirmed
by immunoblotting as described previously (13) using DBL1 protein (expressed
by E. coli and transfected BHK-21 cells) or native PfEMP1 purified from iRBC
membranes (dilution of sera, 1:250).
Rosette disruption assay and serum-induced agglutination assay. The ability
of the immune sera to disrupt rosettes (dilutions of 1:5 to 1:100) was assayed as
described previously (13) using the purified IgG fraction of a Malawian hyper-
immune serum pool and a malaria-naı¨ve Swedish serum as controls.
To investigate immune agglutination of iRBC, trophozoite iRBC (20 h p.i.)
were treated with phosphate-buffered saline containing 100 mM sodium citrate,
washed, resuspended to a hematocrit of 10%, and incubated with the immune
sera (dilutions of 1:50 to 1:100), and agglutinates were scored as described
previously (16).
RESULTS
FCR3S1.2 is recognized by antibodies of semi-immune
Kenyan children. FACS analysis of surface immunofluorescence
with 58 individual sera from semi-immune children, a pool of
sera from local adults and European individuals was created to
investigate whether FCR3S1.2 var1 PfEMP1 was recognized by
antibodies from children in areas of malaria endemicity. In
addition, 7 fresh isolates from local children with uncompli-
cated malaria (see Materials and Methods) and the laboratory
strain A4 were tested as references. All parasites were recog-
nized by the pool of local adult sera (54% average reactivity;
data not shown) but poorly by the pool of European sera (3%
average reactivity), while reactivity with the different sera from
local children fluctuated considerably; on average 18%, varying
between 7 and 36% for the different local isolates and parasite
strains (Fig. 1). FCR3S1.2 iRBC organisms were among the
best recognized parasites by the local adult pool (67% reactiv-
ity; data not shown) and the absolute best recognized parasite
by sera from local children (36% average reactivity), better
recognized than any of the local parasite isolates (Fig. 1). This
suggests that the antigen FCR3S1.2 var1 PfEMP1 displays
strong immunogenicity and indicates the FCR3S1.2 var1
PfEMP1 type to be commonly expressed by wild-type parasites.
The high level of antibody recognition already present in child-
hood supports the idea of FCR3S1.2 iRBC being a parasite
with a phenotype possibly associated with severe disease.
Anti-DBL1 antibodies protect against sequestration upon
parasite challenge in the rat model. Our earlier studies have
demonstrated anti-DBL1 domain antibodies to be protective
against challenges with homologous parasites in vivo (14). To
investigate whether DBL1 domains are able to induce cross-
protective antibodies, three DBL1 domains derived from dif-
ferent parasite clones/strains were selected as immunogens;
the most importance was attached to the DBL1 domain (of
var1) of the clone FCR3S1.2, a parasite that displays a mul-
tiadhesive phenotype and forms rosettes and large autoagglu-
tinates, which makes it a potential model of a parasite express-
ing a PfEMP1 associated with severe malaria—a hypothesis
supported by the immunofluorescence data presented above.
Two additional DBL1 domains were included in order to
analyze the capacity of a composition of DBL1 domains to
induce a broad range of antibodies. The DBL1 domain (var1)
of the clone PAvarO, a parasite that has been adapted to infect
Saimiri monkeys, which also displays a rosetting phenotype and
the DBL1 domain of var5.2 derived from the parasite clone
3D7S8 were selected. Sequence alignment of these DBL1
domains illustrates that they cluster into different groups (see
Fig. S1 in the supplemental material). The sequence similarity
between the DBL1 domains used in our vaccine study varies
between 43 and 57% (DBL1 domain of FCR3S1.2/var5.2,
45%; FCR3S1.2/PAvarO, 43%; var5.2/PAvarO, 57%), sup-
porting the idea that they represent different subtypes of
DBL1 domains.
Animals were immunized with single (FCR3S1.2 or PAvarO)
FIG. 1. Recognition of laboratory strains and local Kenyan isolates
by sera from local children as analyzed by FACS. Fifty-eight sera
obtained from semi-immune children in Kenya were tested for their
ability to react with the surface of seven local parasite isolates and two
laboratory parasite strains. The laboratory strain FCR3S1.2 (dark gray
bar) shows a higher average percentage of surface fluorescence when
incubated with sera from local children than the laboratory strain A4
or any of the local parasites. All parasites tested were well recognized
by a pool of sera from local adults (positive control) and poorly rec-
ognized by a pool of European sera (negative control; data not shown).
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or various DBL1 domains (FCR3S1.2, PAvarO, 3D7 var5.2),
applied sequentially or as a mixture (Table 1) followed by chal-
lenges with iRBC of different antigenic types.
Prior to parasite challenges, the presence of specific anti-
bodies was verified. Sera obtained from groups 1 and 4 showed
strong reactivity with the homologous protein in Western blots
(data not shown) and ELISAs, but very weak or no cross-
reactivity with the DBL1 domains derived from the heterol-
ogous var genes; sera obtained from groups immunized with
several DBL1 domains displayed reactivity against all three
domains, with a higher reactivity against the DBL1 domain of
FCR3S1.2 iRBC. Differences between sera of group 2 (sequen-
tial application) and 3 (mixed application) were small, with
slightly higher reactivity induced in animals of group 2 (see Fig.
S2 in the supplemental material).
Surface fluorescence with the generated sera confirmed the
presence of antibodies able to react with the surface of the live
iRBC. Sera from all groups were tested for their reactivity with
different laboratory strains/clones (FCR3S1.2, R29, FCR3,
F32, Dd2, and FCR3CSA). Fluorescence was strongest using
the homologous parasite FCR3S1.2, but also present as cross-
reactive antibodies against the heterologous parasite strains
R29 and FCR3, while Dd2 and FCR3CSA did not show any
reactivity (see Table S2 in the supplemental material).
Rats from all groups were challenged with various parasite
strains/clones with similar absolute sequestration levels
(FCR3S1.2, 6%; FCR3CSA, 4.5%; and R29, 4.5%). The level
of sequestered iRBC in the lungs was compared to that of
animals immunized with a control antigen (arbitrarily set to
100%) and corrected for uninfected human RBC background
FIG. 2. Inhibition of in vivo sequestration of iRBC in immunized rats. Immunized rats were challenged with iRBC of different parasite
strains/clones. Sequestration of iRBC is expressed as a percentage of that in animals immunized with a control protein. The bars give the mean
values of at least two animals, and error bars are presented when more than two animals were tested. The number of tested animals is indicated
in the bottom of the bars. (A) Animals were immunized with the DBL1 domain of FCR3S1.2 and challenged with iRBC of FCR3S1.2, R29, or
FCR3CSA. (B) Animals were immunized with three DBL1 domains applied as a mix and challenged with iRBC of FCR3S1.2, R29, or FCR3CSA.
(C) Animals were sequentially immunized with three DBL1 domains and challenged with iRBC of FCR3S1.2 and R29. (D) Animals were
immunized with the DBL1 domain of PAvarO and challenged with iRBC of FCR3S1.2, R29, or FCR3CSA.
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values (26). In addition, levels of sequestration of iRBC in
GST-immunized and naı¨ve animals were compared and no
differences in binding levels could be observed (data not
shown).
Rats immunized with the DBL1 domain of FCR3S1.2
alone (group 1) showed a mean reduction of 51% sequestrated
material upon challenge with both the homologous FCR3S1.2
and the heterologous R29 parasite as compared to that of
control animals (Fig. 2A). Similar results were obtained in
group 2 (reduction with 41% and 40% sequestrated material;
Fig. 2B) and group 3 (reduction with 34% and 71% seques-
trated material; Fig. 2C) when challenged with iRBC of
FCR3S1.2 and R29. Almost no reduction was observed upon
challenge with FCR3CSA iRBC in any of the groups (Fig. 2A,
B, and D). Rats immunized with the DBL1 domain of
PAvarO alone (group 4) did not show any reduction of seques-
tration with any of the three different parasite clones (Fig. 2D).
Sequestration levels of iRBC lacking PfEMP1 on their sur-
face are around 45% lower than that of iRBC with PfEMP1
(26), indicating that this remaining binding is PfEMP1 inde-
pendent, possibly mediated by other surface antigens or pas-
sive trapping, revealing our generated anti-DBL1-antibodies
almost completely block the PfEMP1-dependent sequestration
of iRBC.
In addition, we investigated whether the protective effect of
the anti-DBL1-antibodies could be passively transferred from
immunized to naı¨ve animals: iRBC were preincubated in seri-
ally diluted immune sera obtained from immunized rats prior
to injection into naı¨ve rats, and binding levels were compared
to those of iRBC incubated in control sera, revealing a dilu-
tion-dependent inhibitory effect on sequestration of FCR3S1.2
and R29 iRBC (see Fig. S3 in the supplemental material).
Anti-DBL1 antibodies induced by vaccination in monkeys.
Ten monkeys assigned to two different groups were immunized
with the DBL1 domain of FCR3S1.2 or GST, respectively.
Antibody responses against the DBL1 domain were mea-
sured by ELISAs and Western blotting: ELISA endpoint titers
ranged between 1:32,000 and 1:1,000 (Fig. 3A). Sera of all
DBL1 domain-immunized monkeys reacted with recombi-
nant DBL1 protein and recognized PfEMP1 purified from
FCR3S1.2 iRBC membranes in immunoblot assays (Fig. 3B
and C).
Functional analysis of the antibodies revealed their ability to
disrupt rosettes and to agglutinate FCR3S1.2 iRBC. While the
rosetting rates were on average reduced with 11% (dilution,
1:20), 38% (dilution, 1:10) and 40% (dilution, 1:5) with sera
of the DBL1-immunized group, the efficiencies were 7% (di-
lution, 1:5), 4% (dilution, 1:10), and 3% (dilution, 1:20) for
those of the control group (Fig. 4). The same sera showed no
influence on the rosetting capacity of PAvarO iRBC, while sera
raised against the DBL1 domain of PAvarO indeed disrupted
the rosettes of this parasite (data not shown). Sera of all mon-
keys immunized with the DBL1 construct agglutinated
FCR3S1.2 iRBC (dilution from 1:50 to 1:80), while sera of the
control group did not (data not shown).
Anti-DBL1 antibodies protect monkeys against iRBC se-
questration. We have recently advanced a small animal model
visualizing sequestration of iRBC in cynomolgus macaques
(39a). Briefly, to investigate the binding of infected and non-
infected human RBC in the circulation of monkeys, two naı¨ve
FIG. 3. Reactivity of sera generated against the DBL1 domain of
FCR3S1.2 in monkeys. (A) The reactivity of the sera against a His-
tagged recombinant DBL1 protein was measured by ELISA. Sera
obtained from DBL1-immunized monkeys specifically reacted with
the recombinant protein (solid lines), while the prebleed sera did not
(dashed line). Sera obtained from GST-immunized monkeys did not
show any reactivity with the recombinant DBL1 protein in either the
prebleed or the last bleed sera (data not shown). (B) Immunoblot
against recombinant DBL1 protein obtained from electroporated
BHK cells. (C) Immunoblot against PfEMP1 purified from iRBC
membranes visualizing the reactivity to the native protein.
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animals were challenged with 1  108 either infected or non-
infected human RBC and the allocation of the cells was
observed for 60 min. iRBC revealed a binding pattern re-
sembling that of human iRBC in the previously described rat
model, with around 9% of the infected material sequester-
ing in the lungs. Injection of noninfected RBC illustrated a
background binding of human RBC in the lung endothelium
of 3.4% (Fig. 5A).
To investigate the effect of our vaccine, all 10 immunized
monkeys were challenged with FCR3S1.2 iRBC. Analysis of
the lung endothelium revealed that immunization with the
DBL1 construct substantially lowered the number of seques-
tered iRBC. The accumulation of iRBC in animals immunized
with GST was identical to that of the nonimmunized animal
during the pilot experiment. Control animals had 9.6% of the
iRBC sequestered in the lungs 30 min after injection, corre-
sponding well to 8.7% of the iRBC found in the pilot experi-
ment 60 min after injection (Fig. 5A), considering the slow
decrease of the sequestered material during the experiment as
described for the rat model (26) (Fig. 5A). In contrast, mon-
keys immunized with the DBL1 construct had only 6.7% of
the material bound in the lung capillaries. The binding in the
DBL1-immunized monkeys was therefore lowered to 54% on
average compared to that of the control animals (Fig. 5B),
when taking into consideration the unspecific activity of human
RBC, which accounts for 3.4% of the material trapped in the
lungs.
Differences in the sequestration rates between the groups
were assessed with the unpaired t test using Sigma Stat soft-
ware (SPSS, Chicago, IL); a P value less than 0.05 was consid-
ered significant. Comparison of the two groups revealed that
the sequestration levels in the DBL1-immunized group were
statistically lower than that in the control group (P  0.001),
which was likewise the case for sequestration rates including or
corrected for RBC background binding.
DISCUSSION
The lack of antibodies to surface antigens on P. falciparum
iRBC associated with severe disease has been proposed as the
reason why children younger than 5 years of age are most
vulnerable to severe malaria (5–7, 10, 23, 24). The induction of
an early immune response against this subtype of PfEMP1
molecules in those individuals would be essential to prevent
severe disease.
PfEMP1 molecules mediating the sequestration of the iRBC
are among the most promising candidates for an anti-severe
malaria vaccine. Immune responses to this antigen are crucial
for the protection against severe disease, though additional
surface antigens might be involved in protection (1, 5, 7, 10, 23,
24). A potential vaccine candidate is the PfEMP1 of the par-
asite clone FCR3S1.2 studied here, which is able to bind to
multiple host receptors (13, 40), analyzed extensively in our
in vivo sequestration model based on immunocompetent
Sprague-Dawley rats. Histopathological analysis of the sites of
sequestration in the animal model revealed degradation of
FIG. 4. Rosette disruption by immune sera generated in monkeys. The capacity of the immune sera to disrupt rosettes of the parasite FCR3S1.2
was tested: sera of monkeys immunized with the DBL1 domain showed a significantly higher rosette disruption activity than those of monkeys
immunized with a control protein GST. Bars represent the means of two experiments: dark gray bars, serum dilution of 1:5; light gray bars, serum
dilution of 1:10; white bars, serum dilution of 1:20. An asterisk indicates that serum of animal 4150 could not be assayed in dilutions below 1:10
due to unspecific agglutination of RBC.
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iRBC together with the deposition of fibrin-like material
resembling the situation often observed in autopsy material
from patients with severe malaria (26). The PfEMP1 of the
FCR3S1.2 parasite clone is dominantly recognized by immune
sera from semi-immune individuals (Fig. 1), and the adhesive
features have been characterized in great detail, identifying the
DBL1 domain as an important ligand for binding to host cell
receptors (13). Furthermore, a separate study with more than
20 isolates from Ugandan children with severe or uncompli-
cated malaria revealed that immune sera raised against the
DBL1 domain of FCR3S1.2 preferentially recognize para-
sites from severe malaria patients (Normark et al., submitted
for publication). The high immunorecognition of the PfEMP1
of FCR3S1.2 supports the finding that virulence-associated
PfEMP1 factors are at least semiconserved (24) and that early
development of immunity to these virulence factors would
provide protection against lethal malaria infection.
We have previously shown that immunization with the
DBL1 domain can generate biologically functional antibodies
able to disrupt rosettes and parasite agglutinates and block
iRBC adhesion in a rat model (14). Here, we have further
investigated the cross-recognition of these antibodies gener-
ated by immunization with either a single DBL1 domain or
with three DBL1 domains selected from phylogenetically dis-
tant PfEMP1. Sequential or mixed immunization with three
different DBL1 domains did not generate stronger cross-
protective antibodies compared to immunization with the sin-
gle antigen. These data indicate that the cross-boosting effect
between DBL1 domains of different PfEMP1 types is weak
and underline why immunity to malaria requires numerous
clinical episodes to develop.
Antibodies generated against the FCR3S1.2 DBL1 domain
blocked adhesion of both FCR3S1.2 and R29 iRBC with sim-
ilar efficiency (Fig. 2A), while weak inhibition of sequestration
was seen in animals immunized with the PAvarO DBL1 do-
main regardless of the parasite strain used for the challenge
(Fig. 2D). The similarity between the domains of FCR3S1.2
and R29 or PAvarO is 50% or 42%, respectively. Although the
sequence identity between the DBL1 domain of the parasites
R29 and PAvarO is 68%, the PAvarO construct induced no
protection against challenge with R29 iRBC, indicating that
despite the relatively large sequence similarity, the capacity to
induce cross-reactive antibodies varies greatly (32).
Furthermore, a comparison of the sequences used for im-
munization here reveals a divergence between the DBL1x do-
FIG. 5. Inhibition of in vivo sequestration of iRBC in immunized
monkeys. (A) Sequestration of P. falciparum iRBC in macaque mon-
keys. Two naive monkeys were employed to adapt the rat model to
monkeys: step 1 involved injection with uninfected human RBC in
order to control for the unspecific binding of human RBC (first bar),
and step 2 involved injection of iRBC into a naive animal to verify
sequestration of iRBC in the monkey (second bar). In addition, four
monkeys immunized with GST were challenged with iRBC of the
parasite clone FCR3S1.2 and compared to binding in the naive animal
to define a baseline binding of the parasite FCR3S1.2 in this model.
The bars correspond to the percentage of the infected material se-
questrated in the lungs. Gray bars represent individual animals of
group B, and dark gray bars represent the average of the group. (B)
Sequestration in immunized monkeys. The five animals belonging to
group A were challenged with the same parasite in order to study the
effect of the DBL1 immunization; the values are corrected for un-
specific binding (first bar) caused by passive trapping of human RBC as
observed in the pilot experiment. The average binding of iRBC in the
monkeys of the control group B is defined as 100%, and the binding in
the monkeys of group A is related to that. Light bars represent binding
in individual animals, and dark gray bars represent the average value
of each group. An asterisk indicates that animal 1152 of group B could
not be included due to technical problems.
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main of FCR3 var2 CSA and the other domains used for
immunization (sequence similarity to DBL1 FCR3S1.2, 36%;
sequence similarity to DBL1 PAvarO, 37%), explaining the
low level of protection against sequestration of the FCR3CSA
iRBC. This is in line with previous findings that the cross-
immunorecognition between parasites of cerebral and placen-
tal malaria is very limited. These parasites are associated with
different adhesive and antigenic properties, given that placen-
tal parasites express a molecularly very distinct type of
PfEMP1 (3, 28, 33).
Various studies based on DNA or RNA vaccination have
revealed that the immunogenicity of vaccine candidates visu-
alized in rodent models is often not reproducible in primates
or humans (reviewed in reference 15). To prove the immuni-
zation regimen of SFV DBL1 particles and recombinant pro-
tein to generate functional antibody responses in primates,
macaque monkeys were immunized according to our estab-
lished protocol. The immunizations did not induce any adverse
effect in any of the animals, indicating that the antigen itself
and the adjuvant in the SFV system are safe.
The injection of infected and uninfected human RBC into
the circulation of monkeys revealed around 9% of the material
sequestering in the lungs, additional binding was seen in the
bone marrow of the vertebrae, humerus, and hips (39a), while
uninfected human RBC were detected in the heart, indicating
that these cells stay in circulation. This novel primate model
opens the way to study sequestration of iRBC in a physiolog-
ical setting close to humans. Although artificial, it offers the
possibility of investigating the effect of a vaccine aiming at
the prevention of sequestration under flow dynamics and in the
presence of nonmanipulated endothelial cells (26) creating
valuable data that would complete the information gained
from our in vitro experiments. The anti-DBL1 antibodies
blocked iRBC adhesion in four out of five immunized mon-
keys, while the anti-GST antibodies did not show any inhibitory
effect (Fig. 5). Interestingly, in another set of experiments
studying desequestration of iRBC, up to 60% of the seques-
tered iRBC were readily released from their binding sites after
administration of depolymerized heparin into the circulation
(39a), arguing that the binding between the DBL1 domain
and heparan sulfate (26) is one important mechanism also for
iRBC binding in this model.
In conclusion, immunization with the PfEMP1-DBL1 do-
main of a parasite with a phenotype associated with severe
malaria generates protective immunity, as demonstrated in a
rodent and a primate model as well as in in vitro assays. The
presence of anti-DBL1 antibodies reduced the sequestration
of iRBC as efficiently as the removal of the PfEMP1 from the
iRBC surface. This implies that the PfEMP1-dependent se-
questration can to a large extent be completely blocked by the
antibodies induced by the DBL1 domain. The FCR3S1.2
PfEMP1 is as recognized as antigens of other parasites express-
ing variant surface antigens associated with severe disease by
immune sera of both children and adults from areas of malaria
endemicity. The anti-DBL1 antibodies not only blocked
adhesion of parasites with rosetting phenotypes similar to
the homologous parasite but also preferentially recognized
PfEMP1 expressed by parasites from children with severe ma-
laria. These data support further studies on this promising
antigen for the development of an anti-severe malaria vaccine.
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